FDA
-
-
-
-
-
-
-
MannKind gets FDA approval for inhaled insulin in children ages 6 and up
-
-
-
-
-
-
-
MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026
-
-
-
-
-
-
-
Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets
-
-
-
-
-
-
-
MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
-
-
-
-
-
-
-
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)
-
-
-
-
-
-
-
MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix
-
322,969 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

